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Mucosa, comprising epithelial and dendritic cells, are the major sites for Human Immunodeficiency Virus type 1 (HIV-1) transmission. There,
DCs can capture incoming HIV-1 and in turn transfer virus to CD4+ T lymphocytes in a two-phase process, thereby initiating HIV-1
dissemination. We show that the glycosphingolipid Galactosyl Ceramide (GalCer), acting as mucosal epithelial receptor for HIV-1, was expressed
by human monocyte derived immature DCs (iDCs), human primary DCs isolated from blood and mucosal tissue and in situ on mucosal tissue and
acts as HIV-1-gp41 receptor. Blocking both GalCer and CD4 with specific mAbs results in a >95% transfer inhibition of HIV-1 from human
monocyte-derived iDCs to autologous resting T cells. GalCer interaction with HIV-1 controls the early infection-independent phase of HIV-1
transfer to T cells. Thus, GalCer appears as an initial receptor for HIV-1, common to both mucosal epithelial cells and iDCs.
© 2006 Elsevier Inc. All rights reserved.Keywords: Dendritic cells; Galactosyl Ceramide; Mucosa; AIDS; HumanIntroduction
Mucosal surfaces, covered by epithelial cells, are the major
sites for Human Immunodeficiency Virus type 1 (HIV-1)
transmission (Chermann, 1998). Galactosyl ceramide (GalCer),
a glycosphingolipid highly enriched at the luminal pole of
epithelial cells, acts as mucosal receptor for HIV-1. GalCer
binds both HIV-1 envelope glycoproteins gp120 (Bomsel,
1997; Harouse et al., 1991; Yahi et al., 1995) and gp41 (Alfsen
and Bomsel, 2002; Alfsen et al., 2001). Upon ligand binding,
HIV-1 is endocytosed by epithelial cells in a GalCer-dependent
pathway (Alfsen and Bomsel, 2002), transported and released,
intact and still infectious, to the basolateral pole of the
epithelium (Bomsel, 1997). In the lamina propria, widelyAbbreviations: DCs, Dendritic cells; iDCs, immature DCs; GalCer,
Galactosyl Ceramide; HIV-1, Human Immunodeficiency type 1 Virus.
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doi:10.1016/j.virol.2006.11.035distributed immature dendritic cells (iDCs) are able to capture
HIV-1 particles. Upon HIV-1 capture in periphery, iDCs migrate
from peripheral tissues and blood to gain access to lymphoid
organs. During this process, viral particles remain intact and
infectious, suggesting that HIV-1 is internalized by iDCs in
vesicles that protect virus from degradation before recycling to
dendritic cell surface and transfer to CD4+ T cells. This
intracellular journey resembles that of HIV-1 during the GalCer-
and raft-mediated transcytosis across epithelial cells.
Early studies reported that the lectin DC-SIGN (CD209)
expressed on DC subsets from mucosal tissues acted as HIV-1
receptor in virus internalization by DCs for subsequent transfer
to T cells (Geijtenbeek et al., 2000). However, numerous studies
have challenged the role of DC-SIGN as HIV-1 endocytosis-
receptor to facilitate HIV-1 trans-infection, rather supporting a
function of antigen-capturing receptor for DC-SIGN (Baribaud
et al., 2002; Burleigh et al., 2006; Gummuluru et al., 2003;
Moris et al., 2003; Turville et al., 2001, 2002).
DCs express CD4, the main receptor of HIV-1, CCR5, the
predominant co-receptor involved in transmission in vivo and
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2005; Patterson et al., 2001; Rubbert et al., 1998; Zaitseva et al.,
1997). In a first phase independent of DC infection, soon after
HIV-1 exposure, DCs are able to efficiently transfer HIV-1 to T
cells in the absence of DC productive infection (Blauvelt et al.,
1997; Granelli-Piperno et al., 1998; Hladik et al., 1999; Nobile
et al., 2005; Turville et al., 2004). In a second phase, once DC
productive infection is established, it is newly synthesized virus
that are predominantly transferred to T cells (Burleigh et al.,
2006; Lore et al., 2005; Nobile et al., 2005; Turville et al.,
2004). The ability of DCs to stimulate CD4+ Tcells could play a
key role in establishing CD4+ T lymphocyte infection by HIV-1
(Steinman et al., 2003; Teleshova et al., 2003). Our objective
was to determine whether the epithelial receptor GalCer was
expressed on iDCs and could participate in HIV-1 transfer from
iDCs to CD4+ T cells.
Results and discussion
We first investigated the expression of GalCer in various
types of isolated DCs, namely human iDCs, generated in vitro
with well-established method of monocyte differentiation in
presence of GM-CSF and IL-4 (Sallusto and Lanzavecchia,
1994), human circulating DCs purified from PBMC of healthy
volunteers containing two DC populations, one CD123+ and
the other CD11C+, in a 2:3 ratio (not shown), and mature
human colonic mucosal DCs, emigrated from colonic pieces
of healthy donors. GalCer staining, using a anti-GalCer mono-
clonal antibody (mAb) (Ranscht et al., 1982) at 10 μg/ml was
analyzed by flow cytometry (Figs. 1a–e). The human
epithelial HT29 cell line was used as a positive control (Fig.
1a). GalCer was expressed at cell plasma membrane of both
immature primary dendritic cell from blood and iDCs
generated from human monocytes with GM-CSF and either
IL-4 or IL-13 (Figs. 1d, b and c respectively). Additionally,
iDCs matured 24 h in vitro, either by TNF alpha or LPS,
expressed also GalCer (not shown), as well as mature colonic
emigrated dendritic cells (Fig. 1e). Furthermore, expression of
GalCer was also detected in situ by confocal microscopy on
frozen tissue section of human colon. There, GalCer is
localized at the plasma membrane of resident mucosal CD11c+
dendritic cells in the colonic lamina, with a clear dendritic
morphology (Figs. 1h–k). Cells with dendritic morphology
staining positive for GalCer and CD11c were clearly visible in
the lamina propria, characterized as the 40 μm thick layer
underlining the epithelium, itself characterized as GalCer
positive in a comb-like pattern. On 35 cells from the lamina
propria examined in 4 different sections, 28 were CD11c and
GalCer positive, 1 was GalCer positive but CD11c negative,
and 5 cells localized in clusters were CD11c positive but
GalCer negative.
We next investigated whether GalCer could act as gp41
receptor. We have previously shown that GalCer interacted
with gp41 using a conserved motif in the membrane proximal
region (amino acids 649–684 of gp41, referred to as P1 (Alfsen
and Bomsel, 2002; Alfsen et al., 2001)). We therefore asked
whether P1 could bind to iDCs in a GalCer-dependent manner.Incubation of biotinylated-P1 (b-P1) with iDCs for 30 min at
37 °C resulted in b-P1 internalization, as visualized by
confocal microscopy (Fig. 2a), distributed in a punctuated
vesicular pattern throughout the cell cytoplasm. In contrast, no
internalization occurred for a non-specific scrambled b-P1. P1
internalization occurred only when P1 reached a concentration
of 125 micromolar at which it oligomerized (Alfsen and
Bomsel, 2002; Alfsen et al., 2001) or when peptide was made
dimeric by chemical cross-linking (P1 Xlink 5 μM), and not at
5 micromolar when monomeric, similar to its mode of
interaction with epithelial GalCer, as we have shown
previously (Alfsen and Bomsel, 2002). Furthermore, b-P1
binding to surface of iDCs derived with GM-CSF and either
IL-4 or IL-13 was significantly (>50%) inhibited in a similar
amount by anti-GalCer mAb, as measured quantitatively by
flow cytometry (Fig. 2b). The inability to entirely block P1
binding to iDC surface suggests that as we have recently
shown for mucosal epithelial cells (Alfsen et al., 2005), P1-b
first interacts to heparan sulfate proteoglycan attachment
receptor prior to interact with GalCer.
We then asked whether GalCer was involved in HIV-1
uptake by iDCs prior to transfer to autologous resting CD4+ T
lymphocytes. For the transfer assay (Fig. 3a), iDCs were
exposed to low amount of virus to better approximate the
conditions of the initial steps of mucosal transmission in vivo,
namely 0.01 MOI of R5-tropic HIV-1 for 90 min at 37 °C.
After incubation of DCs with HIV-1, to exclude transfer of
non-internalized HIV-1 particles, the remaining surface-bound
viral particles were removed by a short exposure of DCs to
acidic buffer (glycine buffer, pH=2) that dissociates ligand
from receptor (Amara et al., 1999). The extent of virus
transferred to CD4+ T lymphocytes after HIV-1 internalization
by iDCs was determined by measuring p24 antigen in culture
supernatants collected at day 5 after co-culture initiation.
Acidic treatment removes surface bound viruses (Fig. 3a,
insert), and resulted in the transfer of more than 80% of
viruses as compared to transfer in absence of treatment (Fig.
3a), indicating that the majority of HIV-1 transferred from
iDCs to non activated autologous T cells had been first
internalized by iDCs. HIV-1 production by iDCs cultivated
alone after HIV contact but in absence of autologous CD4+ T
target cell could only reach 15% of the amount of virus
produced in the coculture (Fig. 3b, hatched bar) as shown by
others (Blauvelt et al., 1997; Granelli-Piperno et al., 1998;
Hladik et al., 1999; Nobile et al., 2005; Turville et al., 2004)
indicating that in our standard condition HIV-1 production
results from the synergic interaction between iDCs and
autologous CD4+ T target cells and not just from DC
infection.
With this assay, HIV-1 capture by iDCs was evaluated
comparatively in the presence of mAbs (10 μg/ml) specific for
various receptors involved in HIV-1 interaction with target cells,
namely gp41 (2F5 (Muster et al., 1993)), CD4 (function-
blocking RPA-T4 clone), DC-SIGN (function-blocking 1B10
clone (Burleigh et al., 2006)) and GalCer (Ranscht et al., 1982)
pre-incubated for 20 min at room temperature prior to virus
inoculation. As a result, anti-DC-SIGN 1B10 antibody, used at a
Fig. 1. GalCer is expressed by various primary human DC subtypes and acts as receptor for gp41 membrane proximal domain P1. HT29 colonic cell line, used as a
positive control (a), iDCs generated in vitro with IL-4 and GM-CSF (b) or IL-13 and GM-CSF (c), human circulating DC isolated from blood of healthy volunteer
donors (d), or mature DC emigrated from human colon (e) were incubated with anti-GalCer antibody (10 μg/ml) for 30 min at 4 °C, and then with fluorescent anti-IgG3
antibody for 30 min at 4 °C. Cells were analyzed by flow cytometry. As a negative control, an irrelevant mouse isotype matched IgG3 was used as primary antibody.
GalCer expression in iDCs shown in this figure was comparable in all iDCs preparations used in this study. The result with circulating DCs and mature colonic
emigrated DCs are representative of analyses performed with different donors (n=3 and n=2, respectively). Expression of GalCer by resident mucosal dendritic cells
ex vivo was detected in situ on human colon samples. 10 μm thawed sections of human colon samples were fixed in PBS-PFA 4% before staining using mouse IgG3
anti-GalCer or matched isotype control and mouse IgG1 anti-CD11c or matched isotype control antibodies (10 μg/ml) for 1 h at room temperature. Indirect
immunofluorescence allowed detection of GalCer (green) and CD11c positive DCs (red) by two-color confocal microscopy as in (Bomsel et al., 1998). Staining with
matched isotype mouse IgG3 (green) (f) or IgG1 (red) (g) control gives no signal. Arrowhead in (h) shows GalCer staining on epithelial cells. Arrows show CD11c+
GalCer+ double-labeled DCs. One single section at high magnification is shown for GalCer (i), and CD11C (j) staining and the corresponding green and red
fluorescence images were overlaid (k). Co-localization appeared in yellow. Scale bar=10 μM.
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to target cells ((Burleigh et al., 2006; Moris et al., 2006) and
data not shown), did not block HIV-1 transfer from iDCs to
autologous CD4+ Tcells (Fig. 3b) as already shown (Burleigh et
al., 2006). In contrast, anti-GalCer mAb, as well as the broadly
neutralizing 2F5 IgG, specific for gp41 peptide P1 induced a
robust inhibition of HIV-1 transfer (>75%) (Fig. 3b), as
compared to transfer in the absence of mAb or in the presence
of matched isotype controls. The anti-CD4 IgG blocking gp120-CD4 interaction had no detectable effect (Fig. 3b), but in
contrast acted synergistically to anti-GalCer mAb to completely
abolish transfer (>95%) (Fig. 3b).
The second phase of HIV-1 transfer by DCs to T cells
(Turville et al., 2004), namely transfer of newly synthesized
HIV-1 resulting from DC infection, is directly correlated to
DC infection. Of note, DC infection was blocked by the anti-
CD4 antibody, as expected but remained insensitive to anti-
GalCer mAb (Fig. 3c), and even slightly increased, suggesting
Fig. 2. P1 peptide from HIV-1 gp41 binds iDC in a GalCer dependent manner. (a) Oligomeric P1 binds to iDCs. IDCs were incubated with either monomeric b-P1 at
5 μM, b-P1 at a concentration allowing peptide oligomerization: 125 μM, or with dimeric b-P1 upon cross-linking at 5 μM revealed by streptavidin-FITC. No
fluorescent staining was observed on identical cells with streptavidin-FITC in absence of b-P1 (no peptide) or with b-scrambled P1 made of P1 amino acid in a random
order. Samples were observed by confocal microscopy as in (Alfsen and Bomsel, 2002). One single section in each condition is shown. Scale bar=10 μM. (b) P1
binding to iDCs is blocked by anti-GalCer mAbs. IDCs generated with GM-CSF and IL-4 (plain bars) or IL-13 (hatched bars) were preincubated a 4 °C with anti-
GalCer mAb at indicated concentration prior to incubation with b-P1 at 125 μM for 1 h. IDCs were then fixed, labeled with avidin-FITC and analyzed by flow
cytometry. Mean Fluorescent Intensity (>10.000 counts) for each condition was calculated by the ELITE software and results are presented as % of standard condition,
i.e., in presence of control mouse IgG3 isotype. Mean represents standard deviation between at least 4 (for iDCs derived with IL-4) or 2 (for iDCs derived with IL-13)
independent experiments performed in duplicate.
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the virus onto the CD4-mediated one, thereby increasing
infection.
Altogether, several conclusions can be drawn from these
functional assays. First, as anti-CD4 antibody did not block
transfer but blocked infection, the second phase of HIV-1Fig. 3. Role of different receptors during HIV-1 internalization by iDCs. (a) The main
(105/point) were incubated with HIV-1 JR-CSF R5-tropic clone (MOI=0.01) for 90 m
2, 2 min at 4 °C). After washes, cells were further cultured with non-activated autologo
determined at day 5 p.i. by measuring p24gag in supernatants by ELISA and expresse
Results are representative of one experiment out of two. Insert: iDCs were incubated w
to restrict virus binding to iDC cell surface. Cells were then fixed directly (−) or after t
then observed by confocal microscopy. Bar: 10 μm. (b) GalCer is involved in HIV-1 tr
either anti-CD4 function-blocking RPTA-4 clone, anti-DC-SIGN function-blocking
10 μg/ml alone or in combination, or with control mAbs (a mixture of each isotype co
R5-tropic clone) at a MOI of 0.01. IDCs were washed, including one wash with acidi
the absence (hatched bars) or in the presence (closed bars) of autologous non-activate
by measuring p24gag in supernatants by ELISA and expressed as % of p24gag in standa
mean of seven independent experiments performed using iDCs and autologous lymph
anti-DC-SIGN antibodies block infection of iDCs with HIV-1. Anti-CD4 (RPTA-4
isotype control) antibodies were incubated at a dose of 10 μg/ml with iDCs (105/poin
CSF R5-tropic clone) at a MOI of 0.01 for 90 min at 37 °C as in b for transfer experim
5 p.i. by measuring p24gag in cell culture supernatants by ELISA and expressed as %
Results are representative of one experiment out of three.transfer by iDCs occurring after DC productive infection-even
if occurring-is not predominant in our model using resting
autologous T cells as acceptor, in agreement with Moris
(Moris et al., 2006). Second, gp41 and GalCer, most likely by
interacting together, are involved in HIV-1 uptake by iDCs
and transfer to autologous T lymphocytes. As anti-GalCerpool of HIV-1 transferred to resting T cells was first internalized by iDCs. IDCs
in. at 37 °C. When indicated, cells were then treated or not with acidic buffer (pH
us T lymphocytes (5×105/point). Viral production in co-culture supernatant was
d as % of the standard conditions. Error bars represent mean±S.D. of duplicates.
ith HIV-1-GFP (JR-CSF-GFP R5 tropic clone), at MOI=0.01, for 60 min at 4 °C
reatment with acidic buffer (pH 2, 2 min at 4 °C) (+), prior to fixation. Cells were
ansfer by iDCs to autologous non-activated Tcells. IDCs were preincubated with
1B10 antibody, anti-gp41 2F5 blocking IgG, mouse monoclonal anti-GalCer at
ntrol), as indicated. Then, iDCs (105/point) were incubated with HIV-1 (JR-CSF
c buffer, to remove unbound and surface-bound viruses, and further cultivated in
d CD4+ T cells as described in (a). Viral production was determined at day 5 p.i.
rd conditions (100% corresponding to 30 ng/ml of virus). Error bars represent the
ocytes from different donors. (c) Anti-CD4 antibody but neither anti-GalCer nor
clone), anti-GalCer, anti-DC-SIGN (1B10 clone) or control (a mixture of each
t), for 20 min at room temperature. Cells were then inoculated with HIV-1 (JR-
ents and iDCs were then cultivated alone. Viral production was determined at day
of p24gag in standard conditions. Error bars represent mean±S.D. of triplicate.
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responsible for HIV uptake for further transfer to resting
autologous T cells within the early phase of transfer, as
defined by Turville (Turville et al., 2004). Upon endocytosis,
CD4 is internalized by the clathrin-dependent pathway
(Pelchen-Matthews et al., 1993), whereas GalCer uses a raft
dependent-pathway (Alfsen et al., 2001). Accordingly, anti-
GalCer mAb may not have been able to block entirely transfer
since it may have induced rerouting of HIV-1 into the CD4
entry pathway, leading in turn to DC infection. As a result, the
second phase of HIV-1 transfer by DC, that is otherwise not
predominant (see above), would have been increased. Thesynergistic effect of anti-CD4 and anti-GalCer mAbs to bloc-
king transfer may result from blocking both CD4 and GalCer-
mediated HIV internalization pathways impairing rerouting of
the virus from the GalCer (blocked by anti GalCer antibodies)
to the CD4 entry pathway (now blocked by anti-CD4 anti-
bodies), and thereby the small portion of transfer due to DC
infection.
In summary, we have previously shown that HIV-1 crosses
epithelial barrier by using transcytosis after gp41 binding to
epithelial GalCer (Alfsen and Bomsel, 2002; Bomsel, 1997).
The present study suggests that as in mucosal epithelial cells,
iDCs can internalize and transport the virus to its target cells,
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conserved region of gp41, P1. Importantly, P1 is the target of
the two broadly neutralizing IgG 2F5 and 4E10 (Muster et al.,
1993). Mucosal immunization protocols based on P1 to induce
2F5- or 4E10-like HIV-1-neutralizing antibodies are in
progress (Matoba et al., 2004, 2006). Such neutralizing
antibodies would be efficient, not only against mucosal
transmission of HIV-1 by transcytosis across epithelial cells
and dissemination by iDCs, but also against HIV-1 infection of
CD4+ T cells, by interfering with HIV-1 binding to GalCer.
Consequently, gp41 or conserved gp41 domains are good
candidates for future vaccines.
Materials and methods
Cells
Human blood DCs were purified by magnetic separation
using the “Blood dendritic cells isolation kit” (>95% purity,
Miltenyi Biotec, France). Emigrated colonic DCs were
obtained from colonic pieces (0.1 cm2) of healthy donors (Pr.
Soubrane, Cochin Hospital, Paris, France) placed in complete
standard medium at 37 °C in 5% CO2. At day 3, cell culture
medium was filtered through a 40 μm pore meshwork and
contained the emigrated DCs. Monocyte derived iDCs were
generated as described by (Sallusto and Lanzavecchia, 1994) or
(Nobile et al., 2005) from human mononuclear cells from peri-
pheral blood (PBMC) obtained from normal seronegative heal-
thy volunteers' blood by density gradient centrifugation over
Ficoll-Paque PLUS (Pharmacia Biotech, France). CD14
positive (CD14+) monocytes were isolated from PBMC by
negative magnetic depletion using the monocyte isolation kit
(Miltenyi Biotec, France) and a magnetic cell separator
(MACS) according to the manufacturer's instructions (>95%
purity). CD14+ monocytes were cultured at 1 million/ml in
RPMI 1640-glutamine 1 mM, FCS 10% (AbCys S.A., France),
GM-CSF 250 ng/ml and either IL-4 10 ng/ml (Sallusto and
Lanzavecchia, 1994) or IL13 50 ng/ml (Nobile et al., 2005). At
days 2 and 4, an equivalent of a half of the volume was replaced
with cytokine containing fresh medium. Immature dendritic
cells (iDCs) were used at day 7. CD14 negative cells remaining
in the column were eluted and frozen for subsequent use in
transfer experiments.
Flow cytometry
For each marker, 105 cells were incubated with primary
antibody (10 μg/ml) for 30 min at 4 °C, and then with a fluo-
rescent secondary antibody for 30 min at 4 °C. Cells (5000 or
10,000 events) were analyzed by flow cytometry (FACScalibur
with the XL software). The specificity of each antibody was
controlled using an irrelevant antibody matching the isotype of
the primary one, and served as a negative control. The CD1a
and CD14 phenotype of iDCs was verified for each iDCs
preparation used in this study.
To exclude epithelial cell contamination in the mature
emigrated colonic DCs, the following strategy was applied.DCs emigrated from colon were examined just after DCs
emigrated from epidermal. DCs emigrated from epidermis
stain positive for CD1a, and MHC-II and allowed to define a
forward versus side scatter gate. DCs emigrated from colon
exhibited the same forward versus side scatter characteristics
and GalCer staining analyzed in the same gate. Furthermore
epithelial cells are larger cells that were not included in this
gate.
Virus
JRCSF (proviral clone from AIDS Research and Reference
Reagent Program, NIAID) was produced by standard calcium
phosphate transfection technique in 293T cells.
Internalization of HIV-1 or P1 peptide by iDCs
IDCs (105/well) were first incubated for 30 min at 37 °C in
RPMI 1640 supplemented with BSA (Bovine Serum Albumin)
1% and Hepes 10 mM (RPMI-BSA1%–Hepes10 mM). Green
Fluorescent Protein (GFP)-labeled HIV-1 (GFP-HIV-1) (10 ng
of p24gag/100 μl/105DCs corresponding to a multiplicity of
infection (MOI) of 0.01) or biotinylated P1 (b-P1 at indicated
concentration) were added in RPMI-BSA1%–Hepes10 mM for
indicated times. Cells were then washed in ice-cold RPMI-
BSA1%–Hepes10 mM. To remove surface bound virus, cells
were treated for 2 min with ice-cold phosphate-buffered saline
(PBS)–glycine 0.1 M pH 2. DCs were then washed two times in
ice-cold RPMI-BSA1%–Hepes 10 mM and fixed for 20 min
with paraformaldehyde (PFA) 2%. To reveal internalized b-P1,
DCs plasma membranes were permeabilized in PBS-BSA
0.5%–saponin 0.05% and cells were incubated for 1 h with
FITC-labeled avidin (1/300, PIERCE, France).
Confocal microscopy
Labeled cells or tissue sections were mounted in Mowiol and
analyzed by confocal microscopy using a BioRad 1024 confocal
microscope with a Nikon optic, as described earlier (Bomsel et
al., 1998). For double labeling analysis, red (595 nm) and green
(488 nm) emission were scanned sequentially, thereby avoiding
bleed-through from one fluorescent channel into the other.
Consecutive sections were 0.5 μm apart. Images were processed
using the double-labeling Laser Sharp software. Co-localization
appeared as yellow pixels after merging two sections recorded at
the same xz level in each channel.
HIV-1 transfer by iDCs
HIV-1 JR-CSF, at MOI of 0.01 corresponding to 10 ng of
p24 antigen/100 μl/105 iDCs, was inoculated onto iDCs for
90 min at 37 °C. iDCs were then washed once in cold RPMI-
BSA1%–Hepes10 mM and acid treated for 2 min wash with
ice-cold pH=2 glycine buffer (100 μl/105 cells) followed by to
additional washes in RPMI-BSA1%–Hepes10 mM, apart in
Fig. 3a when indicated. 5×104 iDCs were cultured in duplicate
with 5×105 non activated autologous lymphocytes allowing
73A. Magérus-Chatinet et al. / Virology 362 (2007) 67–74iDC-T cell conjugates to form (not shown). Non activated T
lymphocytes were used since iDC-T cell contacts in conjugates
are sufficient to activate CD4+ T lymphocytes allowing HIV-1
replication for 5 days. The extent of virus transferred to CD4+ T
cells was measured in the co-culture supernatants using a
commercial p24 antigen ELISA (Coulter, France) as indicated
by the manufacturer. In transfer inhibition experiments,
blocking antibodies (10 μg/ml) were incubated at 20 °C with
iDCs for 20 min prior to exposure to HIV-1.
HIV-1 infection of iDCs
Protocol was similar as described above for transfer except
that no T lymphocytes were added after incubation of cells with
HIV-1 and washes.
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